Promis Neurosciences (NASDAQ:PMN) Upgraded by Zacks Research to “Hold” Rating

Promis Neurosciences (NASDAQ:PMN) was upgraded by investment analysts at Zacks Research to a “hold” rating in a research note issued to investors on Tuesday,Zacks.com reports.

Other equities research analysts have also issued research reports about the company. Brookline Capital Markets upgraded Promis Neurosciences to a “strong-buy” rating in a research report on Wednesday, May 20th. Wall Street Zen upgraded Promis Neurosciences from a “strong sell” rating to a “sell” rating in a research report on Sunday, May 31st. Finally, HC Wainwright reiterated a “buy” rating and issued a $18.00 price target on shares of Promis Neurosciences in a report on Monday. One investment analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, Promis Neurosciences currently has an average rating of “Moderate Buy” and a consensus target price of $26.50.

Promis Neurosciences Price Performance

Shares of Promis Neurosciences stock opened at $10.20 on Tuesday. Promis Neurosciences has a one year low of $6.27 and a one year high of $39.75. The stock’s 50-day moving average is $10.97 and its 200 day moving average is $12.04. The firm has a market cap of $91.49 million, a price-to-earnings ratio of -0.70 and a beta of -0.19.

Promis Neurosciences (NASDAQ:PMN) last announced its earnings results on Tuesday, May 12th. The company reported ($1.26) EPS for the quarter, missing the consensus estimate of ($1.06) by ($0.20). On average, sell-side analysts expect that Promis Neurosciences will post -4.57 EPS for the current fiscal year.

Insider Transactions at Promis Neurosciences

In other news, Director Patrick D. Kirwin purchased 4,000 shares of the business’s stock in a transaction on Wednesday, April 22nd. The shares were acquired at an average price of $11.33 per share, for a total transaction of $45,320.00. Following the completion of the acquisition, the director owned 4,653 shares in the company, valued at approximately $52,718.49. The trade was a 612.56% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Insiders own 1.50% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in PMN. Ally Bridge Group NY LLC boosted its holdings in Promis Neurosciences by 367.1% in the third quarter. Ally Bridge Group NY LLC now owns 6,233,497 shares of the company’s stock worth $2,649,000 after acquiring an additional 4,899,069 shares in the last quarter. Janus Henderson Group PLC bought a new position in Promis Neurosciences in the first quarter worth approximately $16,418,000. Armistice Capital LLC raised its stake in shares of Promis Neurosciences by 39.1% in the third quarter. Armistice Capital LLC now owns 2,974,518 shares of the company’s stock worth $1,264,000 after purchasing an additional 836,622 shares during the last quarter. Yu Fan purchased a new stake in shares of Promis Neurosciences in the first quarter worth approximately $4,188,000. Finally, Citadel Advisors LLC raised its stake in shares of Promis Neurosciences by 168.1% in the third quarter. Citadel Advisors LLC now owns 170,079 shares of the company’s stock worth $72,000 after purchasing an additional 106,650 shares during the last quarter. Institutional investors own 50.13% of the company’s stock.

More Promis Neurosciences News

Here are the key news stories impacting Promis Neurosciences this week:

• Positive Sentiment: HC Wainwright maintained a Buy rating on Promis Neurosciences and kept an $18 price target, signaling continued analyst optimism about the stock’s upside.
• Positive Sentiment: HC Wainwright raised its FY2026 EPS estimate to ($4.57) from ($4.95), indicating a somewhat improved earnings outlook for Promis Neurosciences.
• Positive Sentiment: The firm also lifted its Q2 2026 EPS estimate to ($1.01) from ($1.54), another relatively better forecast for near-term performance.
• Neutral Sentiment: HC Wainwright issued updated EPS estimates for several future quarters, but these remained losses through FY2027, so the revisions were mixed overall and did not change the broader unprofitable profile of the company.
• Negative Sentiment: Some quarterly estimates were lowered or remain deeply negative, including Q4 2026 at ($1.20), which suggests Promis Neurosciences is still expected to burn cash and post losses for the foreseeable future.

Promis Neurosciences Company Profile

Promis Neurosciences, Inc is a clinical‐stage biopharmaceutical company focused on the discovery and development of novel therapeutics for central nervous system disorders. The company’s research programs target cognitive impairment and other neurological symptoms associated with diseases such as Alzheimer’s disease and multiple sclerosis.

Leveraging a proprietary small‐molecule discovery platform, Promis Neurosciences advances both preclinical and early clinical candidates designed to modulate neural pathways involved in memory, learning and neuroinflammation.